Table 3.
Secondary outcomes of the COVID-VIT trial1.
| Vitamin D3 (n = 52) | Placebo (n = 54) | P value2 | |
|---|---|---|---|
| Mortality, n (%) | 19 (37) | 27 (50) | 0.16 |
| LOS ICU, days | 15.5 (8–22) | 8 (2–15) | 0.001 |
| Hospital stay, days | 20.5 (15–33) | 14.5 (10–23) | 0.007 |
| Mechanical ventilation requirement, n (%) | 33 (63) | 37 (69) | 0.58 |
| Mechanical ventilation, days | 15 (11–19) | 10 (4–16.5) | 0.02 |
| Norepinephrine use, n (%) | 36 (69) | 35 (69) | 0.63 |
| Incidence of nosocomial infection, n (%) | 31 (60) | 22 (41) | 0.05 |
| Positive blood culture, n (%) | 23 (44) | 13 (24) | 0.03 |
1Numerical data are expressed as median (IQR); categorical data as number of cases (percentage).
2P values were calculated by Mann–Whitney U test, χ2 test, or Fisher’s exact test, as appropriate. LOS ICU length of stay in the intensive care unit; 3N is reference range.